Cancer Management and Research
Volume 14, 2022 - Issue
Open access
99
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH
A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
Qingqing Li1 Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou city, People’s Republic of Chinahttps://orcid.org/0000-0001-9631-1441View further author information
, Tong Su2 Department of Medical, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou city, People’s Republic of Chinahttps://orcid.org/0000-0003-4552-6594View further author information
, Xu Zhang3 Department of Hepatobiliary Pancreatic Surgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou city, People’s Republic of ChinaView further author information
, Yanfeng Pan1 Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou city, People’s Republic of ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-2438-4016View further author information
, https://orcid.org/0000-0002-2438-4016View further author information
Shengli Ma4 Department of Infectious Diseases, The People’s Hospital of Yongcheng, Yongcheng city, People’s Republic of Chinahttps://orcid.org/0000-0002-8327-292XView further author information
, Lu Zhang4 Department of Infectious Diseases, The People’s Hospital of Yongcheng, Yongcheng city, People’s Republic of Chinahttps://orcid.org/0000-0002-1567-7773View further author information
, Xianqiang Zhang1 Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou city, People’s Republic of Chinahttps://orcid.org/0000-0002-5430-5198View further author information
& Xiaojuan Gao1 Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou city, People’s Republic of Chinahttps://orcid.org/0000-0003-2707-2381View further author information
show all
Pages 3037-3046
|
Received 24 Jun 2022, Accepted 29 Sep 2022, Published online: 27 Nov 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.